| Literature DB >> 2280612 |
D Macdonald1, Y Z Jiang, A A Gordon, P Mahendra, R Oskam, P A Palmer, C R Franks, A J Barrett.
Abstract
We treated nine patients in first remission from AML with rhIL-2. The toxic effects of rhIL-2 infusion were, malaise, pyrexia, and hypotension, which resolved rapidly on cessation of rhIL-2 infusion. No patient required transfer to an intensive care unit. Following rhIL-2 infusions patients developed eosinophilia, and a modest lymphocytosis, involving both NK cells, and T lymphocytes. Relapse occurred in six patients at a median of 39 weeks from remission. A particular concern was rapid relapse in the two patients with AML FAB type M5. There was no survival advantage from rhIL-2 treatment when compared to a similar group of chemotherapy only treated AML patients from this institution.Entities:
Mesh：
Substances：
Year: 1990 PMID： 2280612 DOI： 10.1016/0145-2126(90)90109-m
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156